ArticleNeuro-oncology advances
Missing diversity in brain tumor trials.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ethnicity in neuro-oncology research: How are we doing and how can we do better?Journal of neuro-oncology · 2024Pooled it
- Artificial intelligence for symptom assessment and patient-reported outcomes in neuro-oncology.Journal of neuro-oncology · 2026Review
- Socioeconomic Factors Associate With Access but not Survival in Neurosurgical Brain Tumor Patients.World neurosurgery · 2025Article
- Immunologic specificity in glioblastoma: Antigen discovery and translational implications.Neuro-oncology advances · 2025Review
- Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review.Cancers · 2025Review
- Low-Grade Glioma Clinical Trials in the United States: A Systematic Review.Life (Basel, Switzerland) · 2024Review
- Developing a computable phenotype for glioblastoma.Neuro-oncology · 2024Article
- Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.Neuro-oncology · 2024Article
- An expert perspective on diversity-oriented standards for assessing sex and gender in clinical research.Frontiers in psychiatry · 2024Article
- Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future.Current oncology reports · 2023Review
- Diversity within the neurosurgical oncology workforce in the United States: A cross-sectional study with proposed strategies to pave the path forward.Neuro-oncology · 2023Article
- Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act.Pediatrics · 2021Article
- Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology.JCO clinical cancer informatics · 2021Article
- Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.Frontiers in oncology · 2021Article
- Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials for brain tumors represent a significant opportunity for both patients and providers to understand and combat a disease with substantial morbidity. The aim of this study was to quantify and map ethnic and racial representation in brain tumor trials and examine the potential gaps in trial recruitment. We also show that these representation gaps persist even in large multicultural cities like New York City.
methodsWe analyzed brain tumor clinical trials registered on www.clinicaltrials.gov between July 1, 2005 and completed on or before November 11, 2017. We used a combination of PubMed/MEDLINE and Google Scholar to find associated publications and obtained trial information as well as patient demographic information (when available) including race or ancestry.
resultsOut of 471 trials, 27% had no published results. Only 28.4% of trials with results reported race or ethnicity of trial participants, with no observed upward trend by year. Whites were significantly overrepresented in trials for metastatic brain tumors (
conclusionsDespite increasing representation in the American population, minorities are underrepresented in brain tumor trials. In addition, despite numerous legal requirements and ethical mandates, published results including race-based information are remarkably absent from 70% of brain tumor trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.